1. Home
  2. BENF vs NSRX Comparison

BENF vs NSRX Comparison

Compare BENF & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beneficient

BENF

Beneficient

HOLD

Current Price

$3.55

Market Cap

53.0M

Sector

Finance

ML Signal

HOLD

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$2.78

Market Cap

53.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BENF
NSRX
Founded
2003
2019
Country
United States
Israel
Employees
55
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.0M
53.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BENF
NSRX
Price
$3.55
$2.78
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$20.50
AVG Volume (30 Days)
477.1K
125.0K
Earning Date
02-17-2026
03-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$30.01
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$2.60
52 Week High
$9.96
$9.99

Technical Indicators

Market Signals
Indicator
BENF
NSRX
Relative Strength Index (RSI) 39.50 25.26
Support Level $0.38 N/A
Resistance Level $4.84 $6.39
Average True Range (ATR) 0.28 0.46
MACD -0.04 -0.19
Stochastic Oscillator 6.77 0.77

Price Performance

Historical Comparison
BENF
NSRX

About BENF Beneficient

Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and a financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: